89bio Inc (ETNB)
7.19
+0.03
(+0.42%)
USD |
NASDAQ |
Oct 04, 16:00
7.19
0.00 (0.00%)
After-Hours: 20:00
89bio Research and Development Expense (Annual): 122.23M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 122.23M |
| December 31, 2022 | 80.80M |
| December 31, 2021 | 70.33M |
| Date | Value |
|---|---|
| December 31, 2020 | 36.20M |
| December 31, 2019 | 21.35M |
| December 31, 2018 | 13.68M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
21.35M
Minimum
2019
122.23M
Maximum
2023
66.18M
Average
70.33M
Median
2021
Research and Development Expense (Annual) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.31M |
| Oragenics Inc | 15.49M |